1. Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction
- Author
-
Akashdip Singh, Jahangheer Shaik, M. Inês Pascoal Ramos, Sol Langermann, Linde Meyaard, Jason Bosiacki, Linjie Tian, Chang Song, Stefan M. Willems, Ana Paucarmayta, Emma J de Ruiter, Saskia V. Vijver, Zachary Cusumano, Dallas Flies, Eline Elshof, and Linda Liu
- Subjects
Extracellular matrix ,Immune system ,medicine.anatomical_structure ,Cancer immunotherapy ,Chemistry ,Effector ,medicine.medical_treatment ,T cell ,medicine ,Cancer research ,Immune receptor ,Receptor ,Decoy - Abstract
Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte associated immunoglobulin-like receptor-1 (LAIR-1). Leukocyte associated immunoglobulin-like receptor-2 (LAIR-2) is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1. We propose that collagens promote immune evasion by interacting with LAIR-1 and that LAIR-2 could release LAIR-1 mediated immune suppression. Analysis of public datasets shows high LAIR-2 expression being associated with a favorable outcome in certain tumors. We designed a dimeric LAIR-2 with a functional IgG1 Fc tail, NC410, and showed that NC410 reduces tumor growth and increases T cell expansion and effector function in humanized tumor models. Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1+immune cells are localized. Our findings show that NC410 might be a powerful new strategy for cancer immunotherapy for immune-excluded tumors.
- Published
- 2020
- Full Text
- View/download PDF